| Name | Title | Contact Details |
|---|
Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.
St. Joseph Orphanage provides a variety of behavioral health services for children, teens, and adults across Southwest Ohio - Locations: Cincinnati & Dayton
X-37 is a pharmaceutical discovery and development company
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.